Health
Daraxonrasib demonstrates initial antitumor activity in RAS-mutant lung cancer
Headline as filed by Medical Xpress. PageNews does not write or rewrite headlines.
PageNews Brief
One publisher, Medical Xpress, has reported this so far, at 21:00 UTC on 2 September 2026.
No other outlet PageNews follows has covered it. If one files, their report will be added to this page and the comparison below will fill out.
The coverage is filed under Health. The publisher's own headline, summary and link is below.
Compiled by PageNews from the report listed below — who filed it and when. No publisher wrote this section.
Coverage from 1 publisher
-
Medical Xpress
Daraxonrasib demonstrates initial antitumor activity in RAS-mutant lung cancer
Daraxonrasib, an oral RAS inhibitor therapy, achieved durable responses in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC) in a phase 1/2 trial led by The University of Texas MD
Read on Medical Xpress →
Reader comments
Comments are written by readers. PageNews does not check them and does not stand behind them, and a name here is a name someone typed, not a person we have identified.
Nobody has commented on this story yet.